Project Title	Funding	Strategic Plan Objective	Institution
Immune signaling in the developing brain in mouse models of ASD	$200,000	Q2.S.A	University of California, Davis
The IL-17 pathway in the rodent model of autism spectrum disorder	$90,000	Q2.S.A	University of Massachusetts, Worcester
Microglia in models of normal brain development, prenatal immune stress and genetic risk for autism	$100,000	Q2.S.A	Harvard University
Bone marrow transplantation and the role of microglia in autism	$62,380	Q2.S.A	University of Virginia
Synergy between genetic risk and placental vulnerability to immune events	$250,874	Q2.S.A	Stanford University
Roles of pro-inflammatory Th17 cells in autism	$249,729	Q2.S.A	New York University
Immune p38-alpha MAPK activation: Convergent mechanism linking autism models	$212,061	Q2.S.A	Florida Atlantic University
The effect of maternal obesity and inflammation on neuronal and microglial functi	$78,250	Q2.S.A	MAYO CLINIC JACKSONVILLE
Developmental Linkage of Metabolic Homeostasis and Sociality	$280,918	Q2.S.A	Indiana University
Autism Spectrum Disorder Diagnostic/Therapeutic Agent	$225,000	Q2.S.A	SPARK2FLAME, INC.
Intra-Prenatal Origins of Neurometabolic Consequences	$319,550	Q2.S.A	University of California, Los Angeles
Mouse model of maternal allergic asthma and offspring autism-like behavioral deficits	$432,669	Q2.S.A	MOUNT HOLYOKE COLLEGE
Project 3: Immune Environment Interaction and Neurodevelopment	$107,931	Q2.S.A	University of California, Davis
Mitochondrial dysfunction due to aberrant mTOR-regulated mitophagy in autism	$183,568	Q2.S.A	Columbia University
GABRB3 and Placental Vulnerability in ASD	$581,537	Q2.S.A	STANFORD UNIVERSITY
Maternal Immune Activation in a Genetic Mouse Model of ASD	$387,961	Q2.S.A	University of Nebraska
DETECTING THE TRANSFER OF MATERNAL ANTIBODIES INTO THE FETAL RHESUS MONKEY BRAIN	$233,500	Q2.S.A	University of California, Davis
PET/MRI investigation of neuroinflammation in autism spectrum disorders	$54,400	Q2.S.A	Massachusetts General Hospital
Folate receptor autoimmunity in Autism Spectrum Disorders	$149,963	Q2.S.A	State University of New York, Downstate Medical Center
The mechanism of the maternal infection risk factor for autism	$0	Q2.S.A	California Institute of Technology
Anti-Neuronal Autoantibodies against Bacterial Polysaccharides in Autism Spectrum Disorders	$0	Q2.S.A	University of Oklahoma Health Sciences Center
MIG-6 tumor suppressor gene protein and ERK 1 and 2 and their association with EGF and EGFR in autistic children	$0	Q2.S.A	Hartwick College
Anti-GAD antibodies in autism	$0	Q2.S.A	Hartwick College

Project Title	Funding	Strategic Plan Objective	Institution
Macrophage Polarization and Utility of in Vivo Therapy with a Brain-Permeable Anti-TNF Agent in Models of Autism	$246,807	Q2.S.A	Emory University
Macrophage Polarization and Utility of in Vivo Therapy with a Brain-Permeable Anti-TNF Agent in Models of Autism	$282,639	Q2.S.A	Emory University
Mechanisms of synaptic alterations in a neuroinflammation model of autism	$0	Q2.S.A	University of Nebraska
Altered placental tryptophan metabolism: A crucial molecular pathway for the fetal programming of neurodevelopmental disorders	$0	Q2.S.A	University of Southern California
MATERNAL BRAIN-REACTIVE ANTIBODIES AND AUTISM SPECTRUM DISORDER	$0	Q2.S.A	Feinstein Institute for Medical Research
Antigenic Specificity and Neurological Effects of Monoclonal Anti-brain Antibodies Isolated from Mothers of a Child with Autism Spectrum Disorder: Toward Protection Studies	$30,000	Q2.S.A	The Feinstein Institute for Medical Research